Oneness Biotech Co Ltd
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II… Read more
Oneness Biotech Co Ltd (4743) - Total Liabilities
Latest total liabilities as of September 2025: NT$872.39 Million TWD
Based on the latest financial reports, Oneness Biotech Co Ltd (4743) has total liabilities worth NT$872.39 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oneness Biotech Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Oneness Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oneness Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Oneness Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vallourec SA
PINK:VLOWY
|
USA | $2.56 Billion |
|
Tianshui Zhongxing Bio-technology Co Ltd
SHE:002772
|
China | CN¥3.16 Billion |
|
SK ETERNIX CO LT
KO:475150
|
Korea | ₩1.19 Trillion |
|
JiangSu JiangHuai Engine Co Ltd
SHE:000816
|
China | CN¥949.07 Million |
|
Hyosung TNC Corp
KO:298020
|
Korea | ₩3.78 Trillion |
|
Shenzhen Sunwin Intelligent
SHE:300044
|
China | CN¥1.03 Billion |
|
Cohort plc
F:C7K
|
Germany | €247.03 Million |
|
Luye Pharma Group Ltd
PINK:LYPHF
|
USA | $15.49 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Oneness Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 37.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oneness Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oneness Biotech Co Ltd (2009–2024)
The table below shows the annual total liabilities of Oneness Biotech Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$859.65 Million | -0.78% |
| 2023-12-31 | NT$866.43 Million | +23.71% |
| 2022-12-31 | NT$700.38 Million | -57.34% |
| 2021-12-31 | NT$1.64 Billion | +1.05% |
| 2020-12-31 | NT$1.62 Billion | +211.85% |
| 2019-12-31 | NT$520.96 Million | +207.09% |
| 2018-12-31 | NT$169.64 Million | +541.03% |
| 2017-12-31 | NT$26.46 Million | -15.74% |
| 2016-12-31 | NT$31.41 Million | -24.71% |
| 2015-12-31 | NT$41.72 Million | -47.77% |
| 2014-12-31 | NT$79.87 Million | -35.50% |
| 2013-12-31 | NT$123.82 Million | +478.35% |
| 2012-12-31 | NT$21.41 Million | +6.59% |
| 2011-12-31 | NT$20.09 Million | +7.72% |
| 2010-12-31 | NT$18.64 Million | +176.39% |
| 2009-12-31 | NT$6.75 Million | -- |